{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:42:36Z","timestamp":1793839356430,"version":"4.6.1"},"reference-count":296,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41575-022-00608-8","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T15:45:23Z","timestamp":1653061523000},"page":"533-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":227,"title":["Breakthroughs in hepatitis C research: from discovery to cure"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-8856","authenticated-orcid":false,"given":"Michael P.","family":"Manns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Maasoumy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"608_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bpg.2012.09.009","volume":"26","author":"B Maasoumy","year":"2012","unstructured":"Maasoumy, B. & Wedemeyer, H. Natural history of acute and chronic hepatitis C. Best. Pr. Res. Clin. Gastroenterol. 26, 401\u2013412 (2012).","journal-title":"Best. Pr. Res. Clin. Gastroenterol."},{"key":"608_CR2","unstructured":"World Health Organization. Global Hepatitis Report. WHO https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789?sequence=1 (2017)."},{"key":"608_CR3","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1056\/NEJM198911303212202","volume":"321","author":"HJ Alter","year":"1989","unstructured":"Alter, H. J. et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321, 1494\u20131500 (1989).","journal-title":"N. Engl. J. Med."},{"key":"608_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1056\/NEJMoa040085","volume":"351","author":"SL Stramer","year":"2004","unstructured":"Stramer, S. L. et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N. Engl. J. Med. 351, 760\u2013768 (2004).","journal-title":"N. Engl. J. Med."},{"key":"608_CR5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"J-M Pawlotsky","year":"2020","unstructured":"Pawlotsky, J.-M. et al. EASL recommendations on treatment of hepatitis C: final update of the series. J. Hepatol. 73, 1170\u20131218 (2020).","journal-title":"J. Hepatol."},{"key":"608_CR6","unstructured":"World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030. WHO https:\/\/apps.who.int\/iris\/handle\/10665\/206453 (2016)."},{"key":"608_CR7","doi-asserted-by":"publisher","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","volume":"3","author":"MP Manns","year":"2017","unstructured":"Manns, M. P. et al. Hepatitis C virus infection. Nat. Rev. Dis. Primers 3, 17006 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"608_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.7326\/0003-4819-77-5-691","volume":"77","author":"HJ Alter","year":"1972","unstructured":"Alter, H. J. et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann. Intern. Med. 77, 691\u2013699 (1972).","journal-title":"Ann. Intern. Med."},{"key":"608_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(74)91412-3","volume":"2","author":"AM Prince","year":"1974","unstructured":"Prince, A. M. et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet 2, 241\u2013246 (1974).","journal-title":"Lancet"},{"key":"608_CR10","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(75)90234-2","volume":"2","author":"HJ Alter","year":"1975","unstructured":"Alter, H. J. et al. Clinical and serological analysis of transfusion-associated hepatitis. Lancet 2, 838\u2013841 (1975).","journal-title":"Lancet"},{"key":"608_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJM197504102921502","volume":"292","author":"SM Feinstone","year":"1975","unstructured":"Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J. & Holland, P. V. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med. 292, 767\u2013770 (1975).","journal-title":"N. Engl. J. Med."},{"key":"608_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(78)90131-9","volume":"1","author":"HJ Alter","year":"1978","unstructured":"Alter, H. J., Purcell, R. H., Holland, P. V. & Popper, H. Transmissible agent in non-A, non-B hepatitis. Lancet 1, 459\u2013463 (1978).","journal-title":"Lancet"},{"key":"608_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0140-6736(78)90132-0","volume":"1","author":"E Tabor","year":"1978","unstructured":"Tabor, E. et al. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1, 463\u2013466 (1978).","journal-title":"Lancet"},{"key":"608_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/infdis\/143.2.210","volume":"143","author":"DW Bradley","year":"1981","unstructured":"Bradley, D. W. et al. Persistent non-A, non-B hepatitis in experimentally infected chimpanzees. J. Infect. Dis. 143, 210\u2013218 (1981).","journal-title":"J. Infect. Dis."},{"key":"608_CR15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jama.1978.03290130049018","volume":"240","author":"MA Hruby","year":"1978","unstructured":"Hruby, M. A. & Schauf, V. Transfusion-related short-incubation hepatitis in hemophilic patients. JAMA 240, 1355\u20131357 (1978).","journal-title":"JAMA"},{"key":"608_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S0140-6736(79)90945-0","volume":"1","author":"RJ Wyke","year":"1979","unstructured":"Wyke, R. J. et al. Transmission of non-A non-B hepatitis to chimpanzees by factor-IX concentrates after fatal complications in patients with chronic liver disease. Lancet 1, 520\u2013524 (1979).","journal-title":"Lancet"},{"key":"608_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/0016-5085(80)90377-7","volume":"79","author":"H Yoshizawa","year":"1980","unstructured":"Yoshizawa, H. et al. Viruslike particles in a plasma fraction (fibrinogen) and in the circulation of apparently healthy blood donors capable of inducing non-A\/non-B hepatitis in humans and chimpanzees. Gastroenterology 79, 512\u2013520 (1980).","journal-title":"Gastroenterology"},{"key":"608_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(85)90055-8","volume":"2","author":"M Colombo","year":"1985","unstructured":"Colombo, M. et al. Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet 2, 1\u20134 (1985).","journal-title":"Lancet"},{"key":"608_CR19","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0140-6736(83)90496-8","volume":"322","author":"R Lane","year":"1983","unstructured":"Lane, R. Non-A, non-b hepatitis from intravenous immunoglobulin. Lancet 322, 974\u2013975 (1983).","journal-title":"Lancet"},{"key":"608_CR20","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S0140-6736(84)91506-X","volume":"2","author":"AM Lever","year":"1984","unstructured":"Lever, A. M., Webster, A. D., Brown, D. & Thomas, H. C. Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 2, 1062\u20131064 (1984).","journal-title":"Lancet"},{"key":"608_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jmv.1890030403","volume":"3","author":"DW Bradley","year":"1979","unstructured":"Bradley, D. W. et al. Experimental infection of chimpanzees with antihemophilic (factor VIII) materials: recovery of virus-like particles associated with non-A, non-B hepatitis. J. Med. Virol. 3, 253\u2013269 (1979).","journal-title":"J. Med. Virol."},{"key":"608_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1056\/NEJM197701132960204","volume":"296","author":"JW Mosley","year":"1977","unstructured":"Mosley, J. W., Redeker, A. G., Feinstone, S. M. & Purcell, R. H. Mutliple hepatitis viruses in multiple attacks of acute viral hepatitis. N. Engl. J. Med. 296, 75\u201378 (1977).","journal-title":"N. Engl. J. Med."},{"key":"608_CR23","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jama.1980.03300360028019","volume":"243","author":"G Norkrans","year":"1980","unstructured":"Norkrans, G., Fr\u00f6sner, G., Hermodsson, S. & Iwarson, S. Multiple hepatitis attacks in drug addicts. JAMA 243, 1056\u20131058 (1980).","journal-title":"JAMA"},{"key":"608_CR24","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(75)92126-1","volume":"2","author":"RM Galbraith","year":"1975","unstructured":"Galbraith, R. M., Eddleston, A. L., Portmann, B., Williams, R. & Gower, P. E. Chronic liver disease developing after outbreak of HBsAG-negative hepatitis in haemodialysis unit. Lancet 2, 886\u2013890 (1975).","journal-title":"Lancet"},{"key":"608_CR25","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/0016-5085(79)90157-4","volume":"77","author":"J Rakela","year":"1979","unstructured":"Rakela, J. & Redeker, A. G. Chronic liver disease after acute non-A, non-B viral hepatitis. Gastroenterology 77, 1200\u20131202 (1979).","journal-title":"Gastroenterology"},{"key":"608_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJM198007173030307","volume":"303","author":"E Tabor","year":"1980","unstructured":"Tabor, E., Seeff, L. B. & Gerety, R. J. Chronic non-A, non-B hepatitis carrier state: transmissible agent documented in one patient over a six-year period. N. Engl. J. Med. 303, 140\u2013143 (1980).","journal-title":"N. Engl. J. Med."},{"key":"608_CR27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/0016-5085(80)90447-3","volume":"79","author":"RL Koretz","year":"1980","unstructured":"Koretz, R. L., Stone, O. & Gitnick, G. L. The long-term course of non-A, non-B post-transfusion hepatitis. Gastroenterology 79, 893\u2013898 (1980).","journal-title":"Gastroenterology"},{"key":"608_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/gut.23.4.270","volume":"23","author":"G Realdi","year":"1982","unstructured":"Realdi, G. et al. Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut 23, 270\u2013275 (1982).","journal-title":"Gut"},{"key":"608_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.1840120409","volume":"12","author":"K Kiyosawa","year":"1990","unstructured":"Kiyosawa, K. et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12, 671\u2013675 (1990).","journal-title":"Hepatology"},{"key":"608_CR30","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJM198104233041701","volume":"304","author":"RD Aach","year":"1981","unstructured":"Aach, R. D. et al. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. N. Engl. J. Med. 304, 989\u2013994 (1981).","journal-title":"N. Engl. J. Med."},{"key":"608_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/infdis\/148.2.254","volume":"148","author":"DW Bradley","year":"1983","unstructured":"Bradley, D. W. et al. Posttransfusion non-A, non-B hepatitis: physicochemical properties of two distinct agents. J. Infect. Dis. 148, 254\u2013265 (1983).","journal-title":"J. Infect. Dis."},{"key":"608_CR32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/0016-5085(85)90150-7","volume":"88","author":"DW Bradley","year":"1985","unstructured":"Bradley, D. W. et al. Posttransfusion non-A, non-B hepatitis in chimpanzees. Physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology 88, 773\u2013779 (1985).","journal-title":"Gastroenterology"},{"key":"608_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359\u2013362 (1989).","journal-title":"Science"},{"key":"608_CR34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-104-4-488","volume":"104","author":"DE Koziol","year":"1986","unstructured":"Koziol, D. E. et al. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann. Intern. Med. 104, 488\u2013495 (1986).","journal-title":"Ann. Intern. Med."},{"key":"608_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.26787","volume":"59","author":"HJ Alter","year":"2014","unstructured":"Alter, H. J. The road not taken or how I learned to love the liver: a personal perspective on hepatitis history. Hepatology 59, 4\u201312 (2014).","journal-title":"Hepatology"},{"key":"608_CR36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1126\/science.2496467","volume":"244","author":"G Kuo","year":"1989","unstructured":"Kuo, G. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244, 362\u2013364 (1989).","journal-title":"Science"},{"key":"608_CR37","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(89)90501-1","volume":"2","author":"M Roggendorf","year":"1989","unstructured":"Roggendorf, M. et al. Antibodies to hepatitis C virus. Lancet 2, 324\u2013325 (1989).","journal-title":"Lancet"},{"key":"608_CR38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(89)90485-6","volume":"2","author":"JI Esteban","year":"1989","unstructured":"Esteban, J. I. et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 2, 294\u2013297 (1989).","journal-title":"Lancet"},{"key":"608_CR39","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0140-6736(89)91016-7","volume":"2","author":"M Colombo","year":"1989","unstructured":"Colombo, M. et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 2, 1006\u20131008 (1989).","journal-title":"Lancet"},{"key":"608_CR40","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S0140-6736(89)91015-5","volume":"2","author":"J Bruix","year":"1989","unstructured":"Bruix, J. et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2, 1004\u20131006 (1989).","journal-title":"Lancet"},{"key":"608_CR41","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"OHCVC Polaris","year":"2017","unstructured":"Polaris, O. H. C. V. C. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2, 161\u2013176 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"608_CR42","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJM199010183231605","volume":"323","author":"JI Esteban","year":"1990","unstructured":"Esteban, J. I. et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N. Engl. J. Med. 323, 1107\u20131112 (1990).","journal-title":"N. Engl. J. Med."},{"key":"608_CR43","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/0140-6736(91)91901-6","volume":"338","author":"No authors listed.","year":"1991","unstructured":"[No authors listed.] Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Lancet 338, 1040\u20131041 (1991).","journal-title":"Lancet"},{"key":"608_CR44","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1056\/NEJM199111073251901","volume":"325","author":"RD Aach","year":"1991","unstructured":"Aach, R. D. et al. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N. Engl. J. Med. 325, 1325\u20131329 (1991).","journal-title":"N. Engl. J. Med."},{"key":"608_CR45","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard, C. W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558\u2013567 (2005).","journal-title":"Lancet Infect. Dis."},{"key":"608_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055285","volume":"8","author":"B Maasoumy","year":"2013","unstructured":"Maasoumy, B. et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 8, e55285 (2013).","journal-title":"PLoS ONE"},{"key":"608_CR47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrgastro.2013.179","volume":"11","author":"M Thursz","year":"2014","unstructured":"Thursz, M. & Fontanet, A. HCV transmission in industrialized countries and resource-constrained areas. Nat. Rev. Gastroenterol. Hepatol. 11, 28\u201335 (2014).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"608_CR48","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/infdis\/143.6.772","volume":"143","author":"GH Scullard","year":"1981","unstructured":"Scullard, G. H. et al. Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J. Infect. Dis. 143, 772\u2013783 (1981).","journal-title":"J. Infect. Dis."},{"key":"608_CR49","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/hep.1840050406","volume":"5","author":"G Dusheiko","year":"1985","unstructured":"Dusheiko, G. et al. Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology 5, 556\u2013560 (1985).","journal-title":"Hepatology"},{"key":"608_CR50","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","volume":"315","author":"JH Hoofnagle","year":"1986","unstructured":"Hoofnagle, J. H. et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315, 1575\u20131578 (1986).","journal-title":"N. Engl. J. Med."},{"key":"608_CR51","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM198911303212204","volume":"321","author":"AM Di Bisceglie","year":"1989","unstructured":"Di Bisceglie, A. M. et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 321, 1506\u20131510 (1989).","journal-title":"N. Engl. J. Med."},{"key":"608_CR52","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","volume":"321","author":"GL Davis","year":"1989","unstructured":"Davis, G. L. et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med. 321, 1501\u20131506 (1989).","journal-title":"N. Engl. J. Med."},{"key":"608_CR53","doi-asserted-by":"publisher","first-page":"700","DOI":"10.7326\/0003-4819-115-9-700","volume":"115","author":"M Shindo","year":"1991","unstructured":"Shindo, M. et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann. Intern. Med. 115, 700\u2013704 (1991).","journal-title":"Ann. Intern. Med."},{"key":"608_CR54","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/jmv.1890340213","volume":"34","author":"S Brillanti","year":"1991","unstructured":"Brillanti, S. et al. Effect of alpha-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study. J. Med. Virol. 34, 136\u2013141 (1991).","journal-title":"J. Med. Virol."},{"key":"608_CR55","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/jmv.1890370311","volume":"37","author":"JA Garson","year":"1992","unstructured":"Garson, J. A. et al. Hepatitis C viraemia rebound after \u2018successful\u2019 interferon therapy in patients with chronic non-A, non-B hepatitis. J. Med. Virol. 37, 210\u2013214 (1992).","journal-title":"J. Med. Virol."},{"key":"608_CR56","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","volume":"139","author":"MG Swain","year":"2010","unstructured":"Swain, M. G. et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139, 1593\u20131601 (2010).","journal-title":"Gastroenterology"},{"key":"608_CR57","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/jvh.12074","volume":"20","author":"MP Manns","year":"2013","unstructured":"Manns, M. P. et al. Long-term clearance of hepatitis C virus following interferon \u03b1-2b or peginterferon \u03b1-2b, alone or in combination with ribavirin. J. Viral Hepat. 20, 524\u2013529 (2013).","journal-title":"J. Viral Hepat."},{"key":"608_CR58","doi-asserted-by":"publisher","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","volume":"127","author":"P Marcellin","year":"1997","unstructured":"Marcellin, P. et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. Med. 127, 875\u2013881 (1997).","journal-title":"Ann. Intern. Med."},{"key":"608_CR59","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1056\/NEJMoa011232","volume":"345","author":"E Jaeckel","year":"2001","unstructured":"Jaeckel, E. et al. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 345, 1452\u20131457 (2001).","journal-title":"N. Engl. J. Med."},{"key":"608_CR60","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/0140-6736(91)91774-O","volume":"338","author":"M Omata","year":"1991","unstructured":"Omata, M. et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 338, 914\u2013915 (1991).","journal-title":"Lancet"},{"key":"608_CR61","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","volume":"337","author":"O Reichard","year":"1991","unstructured":"Reichard, O., Andersson, J., Schvarcz, R. & Weiland, O. Ribavirin treatment for chronic hepatitis C. Lancet 337, 1058\u20131061 (1991).","journal-title":"Lancet"},{"key":"608_CR62","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/hep.1840160307","volume":"16","author":"AM Di Bisceglie","year":"1992","unstructured":"Di Bisceglie, A. M. et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16, 649\u2013654 (1992).","journal-title":"Hepatology"},{"key":"608_CR63","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0016-5085(93)90727-T","volume":"105","author":"S Kakumu","year":"1993","unstructured":"Kakumu, S. et al. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 105, 507\u2013512 (1993).","journal-title":"Gastroenterology"},{"key":"608_CR64","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/0016-5085(94)90131-7","volume":"107","author":"S Brillanti","year":"1994","unstructured":"Brillanti, S. et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107, 812\u2013817 (1994).","journal-title":"Gastroenterology"},{"key":"608_CR65","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","volume":"339","author":"JG McHutchison","year":"1998","unstructured":"McHutchison, J. G. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485\u20131492 (1998).","journal-title":"N. Engl. J. Med."},{"key":"608_CR66","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","volume":"352","author":"T Poynard","year":"1998","unstructured":"Poynard, T. et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352, 1426\u20131432 (1998).","journal-title":"Lancet"},{"key":"608_CR67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","volume":"351","author":"O Reichard","year":"1998","unstructured":"Reichard, O. et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 351, 83\u201387 (1998).","journal-title":"Lancet"},{"key":"608_CR68","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1053\/gast.2002.35950","volume":"123","author":"JG McHutchison","year":"2002","unstructured":"McHutchison, J. G. et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123, 1061\u20131069 (2002).","journal-title":"Gastroenterology"},{"key":"608_CR69","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/clpt.1984.101","volume":"35","author":"RJ Wills","year":"1984","unstructured":"Wills, R. J., Dennis, S., Spiegel, H. E., Gibson, D. M. & Nadler, P. I. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin. Pharmacol. Ther. 35, 722\u2013727 (1984).","journal-title":"Clin. Pharmacol. Ther."},{"key":"608_CR70","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1089-3261(02)00072-7","volume":"7","author":"US Karnam","year":"2003","unstructured":"Karnam, U. S. & Reddy, K. R. Pegylated interferons. Clin. Liver Dis. 7, 139\u2013148 (2003).","journal-title":"Clin. Liver Dis."},{"key":"608_CR71","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns, M. P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958\u2013965 (2001).","journal-title":"Lancet"},{"key":"608_CR72","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1053\/j.gastro.2013.02.013","volume":"144","author":"DE Loomes","year":"2013","unstructured":"Loomes, D. E. & van Zanten, S. V. Bibliometrics of the top 100 clinical articles in digestive disease. Gastroenterology 144, 673\u2013676.e5 (2013).","journal-title":"Gastroenterology"},{"key":"608_CR73","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried, M. W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975\u2013982 (2002).","journal-title":"N. Engl. J. Med."},{"key":"608_CR74","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/j.gastro.2009.08.071","volume":"138","author":"MG Rumi","year":"2010","unstructured":"Rumi, M. G. et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 138, 108\u2013115 (2010).","journal-title":"Gastroenterology"},{"key":"608_CR75","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1053\/j.gastro.2009.10.005","volume":"138","author":"A Ascione","year":"2010","unstructured":"Ascione, A. et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 138, 116\u2013122 (2010).","journal-title":"Gastroenterology"},{"key":"608_CR76","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison, J. G. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361, 580\u2013593 (2009).","journal-title":"N. Engl. J. Med."},{"key":"608_CR77","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1136\/gut.2005.076646","volume":"55","author":"MP Manns","year":"2006","unstructured":"Manns, M. P., Wedemeyer, H. & Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55, 1350\u20131359 (2006).","journal-title":"Gut"},{"key":"608_CR78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jhep.2010.10.032","volume":"55","author":"MW Fried","year":"2011","unstructured":"Fried, M. W., Hadziyannis, S. J., Shiffman, M. L., Messinger, D. & Zeuzem, S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J. Hepatol. 55, 69\u201375 (2011).","journal-title":"J. Hepatol."},{"key":"608_CR79","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa042608","volume":"352","author":"A Mangia","year":"2005","unstructured":"Mangia, A. et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352, 2609\u20132617 (2005).","journal-title":"N. Engl. J. Med."},{"key":"608_CR80","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1053\/j.gastro.2006.02.015","volume":"130","author":"T Berg","year":"2006","unstructured":"Berg, T. et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72\u00a0weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130, 1086\u20131097 (2006).","journal-title":"Gastroenterology"},{"key":"608_CR81","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798\u2013801 (2009).","journal-title":"Nature"},{"key":"608_CR82","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399\u2013401 (2009).","journal-title":"Nature"},{"key":"608_CR83","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105\u20131109 (2009).","journal-title":"Nat. Genet."},{"key":"608_CR84","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/jgh.12475","volume":"29","author":"K Matsuura","year":"2014","unstructured":"Matsuura, K., Watanabe, T. & Tanaka, Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. J. Gastroenterol. Hepatol. 29, 241\u2013249 (2014).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"608_CR85","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/hep.26182","volume":"57","author":"S Yoshio","year":"2013","unstructured":"Yoshio, S. et al. Human blood dendritic cell antigen 3 (BDCA3)+ dendritic cells are a potent producer of interferon-\u03bb in response to hepatitis C virus. Hepatology 57, 1705\u20131715 (2013).","journal-title":"Hepatology"},{"key":"608_CR86","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1478-3231.2011.02449.x","volume":"31","author":"M Romero-Gomez","year":"2011","unstructured":"Romero-Gomez, M., Eslam, M., Ruiz, A. & Maraver, M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int. 31, 443\u2013460 (2011).","journal-title":"Liver Int."},{"key":"608_CR87","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.gastro.2018.09.052","volume":"156","author":"TR O\u2019Brien","year":"2019","unstructured":"O\u2019Brien, T. R., Yang, H. I., Groover, S. & Jeng, W. J. Genetic factors that affect spontaneous clearance of hepatitis C or B virus, response to treatment, and disease progression. Gastroenterology 156, 400\u2013417 (2019).","journal-title":"Gastroenterology"},{"key":"608_CR88","doi-asserted-by":"publisher","first-page":"9524","DOI":"10.1073\/pnas.87.24.9524","volume":"87","author":"N Kato","year":"1990","unstructured":"Kato, N. et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl Acad. Sci. USA 87, 9524\u20139528 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"608_CR89","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1073\/pnas.88.6.2451","volume":"88","author":"QL Choo","year":"1991","unstructured":"Choo, Q. L. et al. Genetic organization and diversity of the hepatitis C virus. Proc. Natl Acad. Sci. USA 88, 2451\u20132455 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"608_CR90","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1128\/jvi.65.3.1105-1113.1991","volume":"65","author":"A Takamizawa","year":"1991","unstructured":"Takamizawa, A. et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J. Virol. 65, 1105\u20131113 (1991).","journal-title":"J. Virol."},{"key":"608_CR91","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1099\/0022-1317-74-11-2391","volume":"74","author":"P Simmonds","year":"1993","unstructured":"Simmonds, P. et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74, 2391\u20132399 (1993).","journal-title":"J. Gen. Virol."},{"key":"608_CR92","doi-asserted-by":"crossref","unstructured":"Francki, R. I. B., Fauquet, C. M., Knudson, D. L. & Brown, F. Classification and Nomenclature of Viruses. Fifth Report of the International Committee on Taxonomy of Viruses. Virology Division of the International Union of Microbiological Societies (Springer, 1991).","DOI":"10.1007\/978-3-7091-9163-7"},{"key":"608_CR93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00430-018-0566-x","volume":"208","author":"V Lohmann","year":"2019","unstructured":"Lohmann, V. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. Med. Microbiol. Immunol. 208, 3\u201324 (2019).","journal-title":"Med. Microbiol. Immunol."},{"key":"608_CR94","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1073\/pnas.88.13.5547","volume":"88","author":"M Hijikata","year":"1991","unstructured":"Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M. & Shimotohno, K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl Acad. Sci. USA 88, 5547\u20135551 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"608_CR95","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1128\/jvi.67.3.1385-1395.1993","volume":"67","author":"A Grakoui","year":"1993","unstructured":"Grakoui, A., Wychowski, C., Lin, C., Feinstone, S. M. & Rice, C. M. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67, 1385\u20131395 (1993).","journal-title":"J. Virol."},{"key":"608_CR96","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1128\/jvi.67.7.3835-3844.1993","volume":"67","author":"R Bartenschlager","year":"1993","unstructured":"Bartenschlager, R., Ahlborn-Laake, L., Mous, J. & Jacobsen, H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3\/4 and NS4\/5 junctions. J. Virol. 67, 3835\u20133844 (1993).","journal-title":"J. Virol."},{"key":"608_CR97","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1128\/jvi.67.7.4017-4026.1993","volume":"67","author":"L Tomei","year":"1993","unstructured":"Tomei, L., Failla, C., Santolini, E., De Francesco, R. & La Monica, N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67, 4017\u20134026 (1993).","journal-title":"J. Virol."},{"key":"608_CR98","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1128\/jvi.68.6.3753-3760.1994","volume":"68","author":"C Failla","year":"1994","unstructured":"Failla, C., Tomei, L. & De Francesco, R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 68, 3753\u20133760 (1994).","journal-title":"J. Virol."},{"key":"608_CR99","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1128\/jvi.69.7.4373-4380.1995","volume":"69","author":"C Lin","year":"1995","unstructured":"Lin, C., Thomson, J. A. & Rice, C. M. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J. Virol. 69, 4373\u20134380 (1995).","journal-title":"J. Virol."},{"key":"608_CR100","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1128\/jvi.69.12.7519-7528.1995","volume":"69","author":"R Bartenschlager","year":"1995","unstructured":"Bartenschlager, R., Lohmann, V., Wilkinson, T. & Koch, J. O. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J. Virol. 69, 7519\u20137528 (1995).","journal-title":"J. Virol."},{"key":"608_CR101","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1128\/jvi.69.3.1575-1581.1995","volume":"69","author":"Y Tanji","year":"1995","unstructured":"Tanji, Y., Hijikata, M., Satoh, S., Kaneko, T. & Shimotohno, K. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J. Virol. 69, 1575\u20131581 (1995).","journal-title":"J. Virol."},{"key":"608_CR102","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/j.1460-2075.1996.tb00329.x","volume":"15","author":"SE Behrens","year":"1996","unstructured":"Behrens, S. E., Tomei, L. & De Francesco, R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15, 12\u201322 (1996).","journal-title":"EMBO J."},{"key":"608_CR103","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1126\/science.282.5390.938","volume":"282","author":"P Pileri","year":"1998","unstructured":"Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 282, 938\u2013941 (1998).","journal-title":"Science"},{"key":"608_CR104","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nature05654","volume":"446","author":"MJ Evans","year":"2007","unstructured":"Evans, M. J. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801\u2013805 (2007).","journal-title":"Nature"},{"key":"608_CR105","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/nature07684","volume":"457","author":"A Ploss","year":"2009","unstructured":"Ploss, A. et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882\u2013886 (2009).","journal-title":"Nature"},{"key":"608_CR106","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","volume":"21","author":"E Scarselli","year":"2002","unstructured":"Scarselli, E. et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21, 5017\u20135025 (2002).","journal-title":"EMBO J."},{"key":"608_CR107","doi-asserted-by":"publisher","first-page":"12766","DOI":"10.1073\/pnas.96.22.12766","volume":"96","author":"V Agnello","year":"1999","unstructured":"Agnello, V., Abel, G., Elfahal, M., Knight, G. B. & Zhang, Q. X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 96, 12766\u201312771 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"608_CR108","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1126\/science.277.5325.570","volume":"277","author":"AA Kolykhalov","year":"1997","unstructured":"Kolykhalov, A. A. et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277, 570\u2013574 (1997).","journal-title":"Science"},{"key":"608_CR109","doi-asserted-by":"publisher","first-page":"8738","DOI":"10.1073\/pnas.94.16.8738","volume":"94","author":"M Yanagi","year":"1997","unstructured":"Yanagi, M., Purcell, R. H., Emerson, S. U. & Bukh, J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl Acad. Sci. USA 94, 8738\u20138743 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"608_CR110","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.285.5424.110","volume":"285","author":"V Lohmann","year":"1999","unstructured":"Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110\u2013113 (1999).","journal-title":"Science"},{"key":"608_CR111","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","volume":"290","author":"KJ Blight","year":"2000","unstructured":"Blight, K. J., Kolykhalov, A. A. & Rice, C. M. Efficient Initiation of HCV RNA replication in cell culture. Science 290, 1972\u20131974 (2000).","journal-title":"Science"},{"key":"608_CR112","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791\u2013796 (2005).","journal-title":"Nat. Med."},{"key":"608_CR113","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature02099","volume":"426","author":"D Lamarre","year":"2003","unstructured":"Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186\u2013189 (2003).","journal-title":"Nature"},{"key":"608_CR114","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1053\/j.gastro.2004.08.002","volume":"127","author":"H Hinrichsen","year":"2004","unstructured":"Hinrichsen, H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127, 1347\u20131355 (2004).","journal-title":"Gastroenterology"},{"key":"608_CR115","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1053\/j.gastro.2007.07.007","volume":"133","author":"T Vanwolleghem","year":"2007","unstructured":"Vanwolleghem, T. et al. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 133, 1144\u20131155 (2007).","journal-title":"Gastroenterology"},{"key":"608_CR116","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon, B. R. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207\u20131217 (2011).","journal-title":"N. Engl. J. Med."},{"key":"608_CR117","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195\u20131206 (2011).","journal-title":"N. Engl. J. Med."},{"key":"608_CR118","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","volume":"365","author":"KE Sherman","year":"2011","unstructured":"Sherman, K. E. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365, 1014\u20131024 (2011).","journal-title":"N. Engl. J. Med."},{"key":"608_CR119","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405\u20132416 (2011).","journal-title":"N. Engl. J. Med."},{"key":"608_CR120","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417\u20132428 (2011).","journal-title":"N. Engl. J. Med."},{"key":"608_CR121","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C Sarrazin","year":"2007","unstructured":"Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767\u20131777 (2007).","journal-title":"Gastroenterology"},{"key":"608_CR122","doi-asserted-by":"publisher","first-page":"20986","DOI":"10.1073\/pnas.1006370107","volume":"107","author":"KP Romano","year":"2010","unstructured":"Romano, K. P., Ali, A., Royer, W. E. & Schiffer, C. A. Drug resistance against HCV NS3\/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl Acad. Sci. USA 107, 20986\u201320991 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"608_CR123","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1053\/j.gastro.2011.05.046","volume":"141","author":"GR Foster","year":"2011","unstructured":"Foster, G. R. et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141, 881\u2013889.e1 (2011).","journal-title":"Gastroenterology"},{"key":"608_CR124","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2013.02.018","volume":"59","author":"MO Silva","year":"2013","unstructured":"Silva, M. O. et al. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2\/3. J. Hepatol. 59, 31\u201337 (2013).","journal-title":"J. Hepatol."},{"key":"608_CR125","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/liv.12070","volume":"33","author":"B Maasoumy","year":"2013","unstructured":"Maasoumy, B. & Manns, M. P. Optimal treatment with boceprevir for chronic HCV infection. Liver Int. 33, 14\u201322 (2013).","journal-title":"Liver Int."},{"issue":"Suppl. 1","key":"608_CR126","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/liv.12079","volume":"33","author":"AB Jesudian","year":"2013","unstructured":"Jesudian, A. B. & Jacobson, I. M. Optimal treatment with telaprevir for chronic HCV infection. Liver Int. 33 (Suppl. 1), 3\u201313 (2013).","journal-title":"Liver Int."},{"key":"608_CR127","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jhep.2013.12.013","volume":"60","author":"JM Vierling","year":"2014","unstructured":"Vierling, J. M. et al. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon\/ribavirin, including prior null response. J. Hepatol. 60, 748\u2013756 (2014).","journal-title":"J. Hepatol."},{"key":"608_CR128","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/gutjnl-2013-305667","volume":"63","author":"M Colombo","year":"2014","unstructured":"Colombo, M. et al. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut 63, 1150\u20131158 (2014).","journal-title":"Gut"},{"key":"608_CR129","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jhep.2014.08.052","volume":"62","author":"SC Gordon","year":"2015","unstructured":"Gordon, S. C. et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J. Hepatol. 62, 286\u2013293 (2015).","journal-title":"J. Hepatol."},{"key":"608_CR130","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1053\/j.gastro.2013.07.051","volume":"145","author":"F Poordad","year":"2013","unstructured":"Poordad, F. et al. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection\u2013a randomized trial. Gastroenterology 145, 1035\u20131044.e5 (2013).","journal-title":"Gastroenterology"},{"key":"608_CR131","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","volume":"59","author":"C H\u00e9zode","year":"2013","unstructured":"H\u00e9zode, C. et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J. Hepatol. 59, 434\u2013441 (2013).","journal-title":"J. Hepatol."},{"key":"608_CR132","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1097\/MEG.0000000000000121","volume":"26","author":"B Maasoumy","year":"2014","unstructured":"Maasoumy, B. et al. Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. Eur. J. Gastroenterol. Hepatol. 26, 836\u2013845 (2014).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"608_CR133","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin, C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J. Hepatol. 64, 486\u2013504 (2016).","journal-title":"J. Hepatol."},{"key":"608_CR134","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1128\/JVI.01360-09","volume":"84","author":"JA Lemm","year":"2010","unstructured":"Lemm, J. A. et al. Identification of hepatitis C virus NS5A inhibitors. J. Virol. 84, 482\u2013491 (2010).","journal-title":"J. Virol."},{"key":"608_CR135","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96\u2013100 (2010).","journal-title":"Nature"},{"key":"608_CR136","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216\u2013224 (2012).","journal-title":"N. Engl. J. Med."},{"key":"608_CR137","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns, M. et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384, 1597\u20131605 (2014).","journal-title":"Lancet"},{"key":"608_CR138","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. & Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 61, S45\u2013S57 (2014).","journal-title":"J. Hepatol."},{"key":"608_CR139","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1111\/jgh.13379","volume":"31","author":"L Wei","year":"2016","unstructured":"Wei, L. et al. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J. Gastroenterol. Hepatol. 31, 1860\u20131867 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"608_CR140","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/cid\/ciu265","volume":"59","author":"GM Abraham","year":"2014","unstructured":"Abraham, G. M. & Spooner, L. M. Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks. Clin. Infect. Dis. 59, 411\u2013415 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"608_CR141","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1128\/AAC.49.5.2059-2069.2005","volume":"49","author":"SW Ludmerer","year":"2005","unstructured":"Ludmerer, S. W. et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob. Agents Chemother. 49, 2059\u20132069 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"608_CR142","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"IM Jacobson","year":"2013","unstructured":"Jacobson, I. M. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368, 1867\u20131877 (2013).","journal-title":"N. Engl. J. Med."},{"key":"608_CR143","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/cid\/civ973","volume":"62","author":"C H\u00f6ner Zu Siederdissen","year":"2016","unstructured":"H\u00f6ner Zu Siederdissen, C. et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin. Infect. Dis. 62, 561\u2013567 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"608_CR144","doi-asserted-by":"publisher","first-page":"ofaa040","DOI":"10.1093\/ofid\/ofaa040","volume":"7","author":"B Schulte","year":"2020","unstructured":"Schulte, B. et al. Frequency of potential drug-drug interactions in the changing field of HCV therapy. Open Forum Infect. Dis. 7, ofaa040 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"608_CR145","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz, E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878\u20131887 (2013).","journal-title":"N. Engl. J. Med."},{"key":"608_CR146","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa1208953","volume":"368","author":"EJ Gane","year":"2013","unstructured":"Gane, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34\u201344 (2013).","journal-title":"N. Engl. J. Med."},{"key":"608_CR147","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns, M. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384, 414\u2013426 (2014).","journal-title":"Lancet"},{"key":"608_CR148","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson, I. M. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384, 403\u2013413 (2014).","journal-title":"Lancet"},{"key":"608_CR149","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1473-3099(14)71002-3","volume":"15","author":"KR Reddy","year":"2015","unstructured":"Reddy, K. R. et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect. Dis. 15, 27\u201335 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"608_CR150","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz, E. et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384, 1756\u20131765 (2014).","journal-title":"Lancet"},{"key":"608_CR151","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1053\/j.gastro.2015.10.013","volume":"150","author":"MS Sulkowski","year":"2016","unstructured":"Sulkowski, M. S. et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 Infection. Gastroenterology 150, 419\u2013429 (2016).","journal-title":"Gastroenterology"},{"key":"608_CR152","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/hep.28467","volume":"64","author":"P Kwo","year":"2016","unstructured":"Kwo, P. et al. Simeprevir plus sofosbuvir (12 and 8\u00a0weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 64, 370\u2013380 (2016).","journal-title":"Hepatology"},{"key":"608_CR153","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/hep.28422","volume":"64","author":"E Lawitz","year":"2016","unstructured":"Lawitz, E. et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 64, 360\u2013369 (2016).","journal-title":"Hepatology"},{"key":"608_CR154","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/gutjnl-2014-307498","volume":"64","author":"C H\u00e9zode","year":"2015","unstructured":"H\u00e9zode, C. et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 64, 948\u2013956 (2015).","journal-title":"Gut"},{"key":"608_CR155","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1053\/j.gastro.2014.10.007","volume":"148","author":"GJ Dore","year":"2015","unstructured":"Dore, G. J. et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 148, 355\u2013366.e1 (2015).","journal-title":"Gastroenterology"},{"key":"608_CR156","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3748\/wjg.v22.i12.3418","volume":"22","author":"I Jacobson","year":"2016","unstructured":"Jacobson, I. et al. Daclatasvir vs telaprevir plus peginterferon alfa\/ribavirin for hepatitis C virus genotype 1. World J. Gastroenterol. 22, 3418\u20133431 (2016).","journal-title":"World J. Gastroenterol."},{"key":"608_CR157","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","volume":"70","author":"PS Belperio","year":"2019","unstructured":"Belperio, P. S., Shahoumian, T. A., Loomis, T. P., Mole, L. A. & Backus, L. I. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3. J. Hepatol. 70, 15\u201323 (2019).","journal-title":"J. Hepatol."},{"key":"608_CR158","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson, D. R. et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61, 1127\u20131135 (2015).","journal-title":"Hepatology"},{"key":"608_CR159","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/hep.28473","volume":"63","author":"V Leroy","year":"2016","unstructured":"Leroy, V. et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 63, 1430\u20131441 (2016).","journal-title":"Hepatology"},{"key":"608_CR160","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski, M. S., Jacobson, I. M. & Nelson, D. R. Daclatasvir plus sofosbuvir for HCV infection. N. Engl. J. Med. 370, 1560\u20131561 (2014).","journal-title":"N. Engl. J. Med."},{"key":"608_CR161","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"P Ferenci","year":"2014","unstructured":"Ferenci, P. et al. ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370, 1983\u20131992 (2014).","journal-title":"N. Engl. J. Med."},{"key":"608_CR162","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad, F. et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 370, 1973\u20131982 (2014).","journal-title":"N. Engl. J. Med."},{"key":"608_CR163","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley, K. V. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370, 1879\u20131888 (2014).","journal-title":"N. Engl. J. Med."},{"key":"608_CR164","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483\u20131493 (2014).","journal-title":"N. Engl. J. Med."},{"key":"608_CR165","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889\u20131898 (2014).","journal-title":"N. Engl. J. Med."},{"key":"608_CR166","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","volume":"147","author":"P Andreone","year":"2014","unstructured":"Andreone, P. et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147, 359\u2013365.e1 (2014).","journal-title":"Gastroenterology"},{"key":"608_CR167","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jhep.2015.08.015","volume":"64","author":"GJ Dore","year":"2016","unstructured":"Dore, G. J. et al. Efficacy and safety of ombitasvir\/paritaprevir\/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I\/II trials. J. Hepatol. 64, 19\u201328 (2016).","journal-title":"J. Hepatol."},{"key":"608_CR168","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000355615","volume":"38","author":"DA Goodkin","year":"2013","unstructured":"Goodkin, D. A., Bieber, B., Gillespie, B., Robinson, B. M. & Jadoul, M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am. J. Nephrol. 38, 405\u2013412 (2013).","journal-title":"Am. J. Nephrol."},{"key":"608_CR169","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","volume":"54","author":"BJ Kirby","year":"2015","unstructured":"Kirby, B. J., Symonds, W. T., Kearney, B. P. & Mathias, A. A. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin. Pharmacokinet. 54, 677\u2013690 (2015).","journal-title":"Clin. Pharmacokinet."},{"key":"608_CR170","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/liv.14391","volume":"40","author":"V Ohlendorf","year":"2020","unstructured":"Ohlendorf, V. & Maasoumy, B. Renal function in HCV therapy: just another thing to ignore? Liver Int. 40, 1018\u20131020 (2020).","journal-title":"Liver Int."},{"key":"608_CR171","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","volume":"65","author":"A Desnoyer","year":"2016","unstructured":"Desnoyer, A. et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J. Hepatol. 65, 40\u201347 (2016).","journal-title":"J. Hepatol."},{"key":"608_CR172","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","volume":"150","author":"PJ Pockros","year":"2016","unstructured":"Pockros, P. J. et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150, 1590\u20131598 (2016).","journal-title":"Gastroenterology"},{"key":"608_CR173","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/apt.13790","volume":"44","author":"R Flisiak","year":"2016","unstructured":"Flisiak, R. et al. Real-world effectiveness and safety of ombitasvir\/paritaprevir\/ritonavir\u2009\u00b1\u2009dasabuvir\u2009\u00b1\u2009ribavirin in hepatitis C: AMBER study. Aliment. Pharmacol. Ther. 44, 946\u2013956 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"608_CR174","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/liv.13102","volume":"36","author":"V Saxena","year":"2016","unstructured":"Saxena, V. et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 36, 807\u2013816 (2016).","journal-title":"Liver Int."},{"key":"608_CR175","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S2468-1253(19)30417-0","volume":"5","author":"E Lawitz","year":"2020","unstructured":"Lawitz, E. et al. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. Lancet Gastroenterol. Hepatol. 5, 918\u2013926 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"608_CR176","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/liv.13336","volume":"37","author":"T Li","year":"2017","unstructured":"Li, T., Qu, Y., Guo, Y., Wang, Y. & Wang, L. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int. 37, 974\u2013981 (2017).","journal-title":"Liver Int."},{"key":"608_CR177","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","volume":"71","author":"SM Borgia","year":"2019","unstructured":"Borgia, S. M. et al. Sofosbuvir\/velpatasvir for 12\u00a0weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J. Hepatol. 71, 660\u2013665 (2019).","journal-title":"J. Hepatol."},{"key":"608_CR178","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"E Lawitz","year":"2015","unstructured":"Lawitz, E. et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous. Lancet 385, 1075\u20131086 (2015).","journal-title":"Lancet"},{"key":"608_CR179","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","volume":"152","author":"P Kwo","year":"2017","unstructured":"Kwo, P. et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 152, 164\u2013175.e4 (2017).","journal-title":"Gastroenterology"},{"key":"608_CR180","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth, D. et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386, 1537\u20131545 (2015).","journal-title":"Lancet"},{"key":"608_CR181","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1128\/AAC.04226-14","volume":"59","author":"P Krishnan","year":"2015","unstructured":"Krishnan, P. et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob. Agents Chemother. 59, 979\u2013987 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"608_CR182","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1128\/AAC.04619-14","volume":"59","author":"W Kati","year":"2015","unstructured":"Kati, W. et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob. Agents Chemother. 59, 1505\u20131511 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"608_CR183","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/AAC.02524-15","volume":"60","author":"G Cheng","year":"2016","unstructured":"Cheng, G. et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob. Agents Chemother. 60, 1847\u20131853 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"608_CR184","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld, J. J. et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 Infection. N. Engl. J. Med. 373, 2599\u20132607 (2015).","journal-title":"N. Engl. J. Med."},{"key":"608_CR185","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster, G. R. et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 Infection. N. Engl. J. Med. 373, 2608\u20132617 (2015).","journal-title":"N. Engl. J. Med."},{"key":"608_CR186","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","volume":"155","author":"R Esteban","year":"2018","unstructured":"Esteban, R. et al. Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology 155, 1120\u20131127.e4 (2018).","journal-title":"Gastroenterology"},{"key":"608_CR187","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"J-M Pawlotsky","year":"2018","unstructured":"Pawlotsky, J.-M. et al. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 69, 461\u2013511 (2018).","journal-title":"J. Hepatol."},{"key":"608_CR188","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jhep.2018.08.029","volume":"70","author":"LM Stamm","year":"2019","unstructured":"Stamm, L. M., Brainard, D. M. & McHutchison, J. G. Sofosbuvir\/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: response to EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 70, 561\u2013562 (2019).","journal-title":"J. Hepatol."},{"key":"608_CR189","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","volume":"69","author":"M Puoti","year":"2018","unstructured":"Puoti, M. et al. High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1-6 patients without cirrhosis. J. Hepatol. 69, 293\u2013300 (2018).","journal-title":"J. Hepatol."},{"key":"608_CR190","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns, X. et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect. Dis. 17, 1062\u20131068 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"608_CR191","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem, S. et al. Glecaprevir-pibrentasvir for 8 or 12\u00a0weeks in HCV genotype 1 or 3 infection. N. Engl. J. Med. 378, 354\u2013369 (2018).","journal-title":"N. Engl. J. Med."},{"key":"608_CR192","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/hep.29541","volume":"67","author":"D Wyles","year":"2018","unstructured":"Wyles, D. et al. Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology 67, 514\u2013523 (2018).","journal-title":"Hepatology"},{"key":"608_CR193","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown","year":"2020","unstructured":"Brown, R. S. et al. Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. J. Hepatol. 72, 441\u2013449 (2020).","journal-title":"J. Hepatol."},{"key":"608_CR194","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","volume":"63","author":"X Forns","year":"2015","unstructured":"Forns, X. et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J. Hepatol. 63, 564\u2013572 (2015).","journal-title":"J. Hepatol."},{"key":"608_CR195","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","volume":"154","author":"J Dietz","year":"2018","unstructured":"Dietz, J. et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology 154, 976\u2013988.e4 (2018).","journal-title":"Gastroenterology"},{"key":"608_CR196","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3851\/IMP3181","volume":"23","author":"D Wyles","year":"2017","unstructured":"Wyles, D. et al. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir. Ther. 23, 229\u2013238 (2017).","journal-title":"Antivir. Ther."},{"key":"608_CR197","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jiac.2018.02.008","volume":"24","author":"KH Peiffer","year":"2018","unstructured":"Peiffer, K. H. et al. Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. J. Infect. Chemother. 24, 524\u2013530 (2018).","journal-title":"J. Infect. Chemother."},{"key":"608_CR198","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.29081","volume":"66","author":"F Poordad","year":"2017","unstructured":"Poordad, F. et al. Glecaprevir and pibrentasvir for 12\u00a0weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 66, 389\u2013397 (2017).","journal-title":"Hepatology"},{"key":"608_CR199","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.29671","volume":"67","author":"F Poordad","year":"2018","unstructured":"Poordad, F. et al. Glecaprevir\/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 67, 1253\u20131260 (2018).","journal-title":"Hepatology"},{"key":"608_CR200","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jhep.2019.01.031","volume":"70","author":"D Wyles","year":"2019","unstructured":"Wyles, D. et al. Retreatment of patients who failed glecaprevir\/pibrentasvir treatment for hepatitis C virus infection. J. Hepatol. 70, 1019\u20131023 (2019).","journal-title":"J. Hepatol."},{"key":"608_CR201","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1111\/liv.14201","volume":"39","author":"T Papaluca","year":"2019","unstructured":"Papaluca, T. et al. Retreatment with elbasvir, grazoprevir, sofosbuvir\u2009\u00b1\u2009ribavirin is effective for GT3 and GT1\/4\/6 HCV infection after relapse. Liver Int. 39, 2285\u20132290 (2019).","journal-title":"Liver Int."},{"key":"608_CR202","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourli\u00e8re","year":"2017","unstructured":"Bourli\u00e8re, M. et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N. Engl. J. Med. 376, 2134\u20132146 (2017).","journal-title":"N. Engl. J. Med."},{"key":"608_CR203","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1055\/a-1217-7669","volume":"58","author":"J Vermehren","year":"2020","unstructured":"Vermehren, J. et al. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: results from the German Hepatitis C-Registry (DHC-R). Z. Gastroenterol. 58, 841\u2013846 (2020).","journal-title":"Z. Gastroenterol."},{"key":"608_CR204","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jhep.2021.02.024","volume":"75","author":"MT Martin","year":"2021","unstructured":"Martin, M. T., Patel, S., Kulik, L. & Chan, C. Glecaprevir\/pibrentasvir\u2009+\u2009sofosbuvir\u2009+\u2009ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings. J. Hepatol. 75, 251\u2013254 (2021).","journal-title":"J. Hepatol."},{"key":"608_CR205","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jhep.2020.11.017","volume":"74","author":"J Dietz","year":"2021","unstructured":"Dietz, J. et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J. Hepatol. 74, 801\u2013810 (2021).","journal-title":"J. Hepatol."},{"key":"608_CR206","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1055\/a-1131-8058","volume":"58","author":"B Bernhard","year":"2020","unstructured":"Bernhard, B. & Stickel, F. Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir\/pibrentasvir, and ribavirin: a case report. Z. Gastroenterol. 58, 451\u2013455 (2020).","journal-title":"Z. Gastroenterol."},{"key":"608_CR207","doi-asserted-by":"publisher","first-page":"ofaa095","DOI":"10.1093\/ofid\/ofaa095","volume":"7","author":"DS Fierer","year":"2020","unstructured":"Fierer, D. S. & Wyles, D. L. Re-treatment of hepatitis c infection after multiple failures of direct-acting antiviral therapy. Open Forum Infect. Dis. 7, ofaa095 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"608_CR208","doi-asserted-by":"publisher","DOI":"10.1055\/a-1649-8931","author":"TL Tergast","year":"2021","unstructured":"Tergast, T. L. et al. Glecaprevir\/pibrentasvir\u2009+\u2009sofosbuvir\u2009+\u2009ribavirin als reserveregime nach sofosbuvir\u2009+\u2009velpatasvir\u2009+\u2009voxilaprevir re-therapieversagen. Z. Gastroenterol. https:\/\/doi.org\/10.1055\/a-1649-8931 (2021).","journal-title":"Z. Gastroenterol."},{"key":"608_CR209","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","volume":"154","author":"JM Gottwein","year":"2018","unstructured":"Gottwein, J. M. et al. Efficacy of NS5A inhibitors against hepatitis c virus genotypes 1-7 and escape variants. Gastroenterology 154, 1435\u20131448 (2018).","journal-title":"Gastroenterology"},{"key":"608_CR210","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry, M. P. et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N. Engl. J. Med. 373, 2618\u20132628 (2015).","journal-title":"N. Engl. J. Med."},{"key":"608_CR211","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton, M. et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149, 649\u2013659 (2015).","journal-title":"Gastroenterology"},{"key":"608_CR212","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","volume":"16","author":"M Manns","year":"2016","unstructured":"Manns, M. et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect. Dis. 16, 685\u2013697 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"608_CR213","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","volume":"65","author":"MCM Cheung","year":"2016","unstructured":"Cheung, M. C. M. et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 65, 741\u2013747 (2016).","journal-title":"J. Hepatol."},{"key":"608_CR214","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/apt.13343","volume":"42","author":"K Deterding","year":"2015","unstructured":"Deterding, K. et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment. Pharmacol. Ther. 42, 889\u2013901 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"608_CR215","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","volume":"65","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer, M. et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J. Hepatol. 65, 692\u2013699 (2016).","journal-title":"J. Hepatol."},{"key":"608_CR216","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","volume":"154","author":"O El-Sherif","year":"2018","unstructured":"El-Sherif, O. et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 154, 2111\u20132121.e8 (2018).","journal-title":"Gastroenterology"},{"key":"608_CR217","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","volume":"1","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol. Hepatol. 1, 122\u2013132 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"608_CR218","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","volume":"65","author":"LS Belli","year":"2016","unstructured":"Belli, L. S. et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J. Hepatol. 65, 524\u2013531 (2016).","journal-title":"J. Hepatol."},{"key":"608_CR219","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","volume":"67","author":"JM Pascasio","year":"2017","unstructured":"Pascasio, J. M. et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J. Hepatol. 67, 1168\u20131176 (2017).","journal-title":"J. Hepatol."},{"key":"608_CR220","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","volume":"64","author":"GR Foster","year":"2016","unstructured":"Foster, G. R. et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 64, 1224\u20131231 (2016).","journal-title":"J. Hepatol."},{"key":"608_CR221","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/hep.29097","volume":"65","author":"C Fern\u00e1ndez Carrillo","year":"2017","unstructured":"Fern\u00e1ndez Carrillo, C. et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology 65, 1810\u20131822 (2017).","journal-title":"Hepatology"},{"key":"608_CR222","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1097\/MEG.0000000000001386","volume":"31","author":"L Sandmann","year":"2019","unstructured":"Sandmann, L. et al. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. Eur. J. Gastroenterol. Hepatol. 31, 1049\u20131056 (2019).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"608_CR223","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cgh.2017.06.024","volume":"16","author":"S Samur","year":"2018","unstructured":"Samur, S. et al. Cost effectiveness of pre- vs post-liver transplant hepatitis C treatment with direct-acting antivirals. Clin. Gastroenterol. Hepatol. 16, 115\u2013122.e10 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"Suppl. 1","key":"608_CR224","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/ajt.12581","volume":"14","author":"WR Kim","year":"2014","unstructured":"Kim, W. R. et al. OPTN\/SRTR 2012 annual data report: liver. Am. J. Transpl. 14 (Suppl. 1), 69\u201396 (2014).","journal-title":"Am. J. Transpl."},{"key":"608_CR225","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/hep.21090","volume":"43","author":"A Blasco","year":"2006","unstructured":"Blasco, A. et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43, 492\u2013499 (2006).","journal-title":"Hepatology"},{"key":"608_CR226","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","volume":"371","author":"PY Kwo","year":"2014","unstructured":"Kwo, P. Y. et al. An interferon-free antiviral regimen for HCV after liver transplantation. N. Engl. J. Med. 371, 2375\u20132382 (2014).","journal-title":"N. Engl. J. Med."},{"key":"608_CR227","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/hep.30046","volume":"68","author":"N Reau","year":"2018","unstructured":"Reau, N. et al. Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology 68, 1298\u20131307 (2018).","journal-title":"Hepatology"},{"key":"608_CR228","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jhep.2018.05.039","volume":"69","author":"K Agarwal","year":"2018","unstructured":"Agarwal, K. et al. Sofosbuvir\/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J. Hepatol. 69, 603\u2013607 (2018).","journal-title":"J. Hepatol."},{"key":"608_CR229","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/hep.25653","volume":"55","author":"JJ Kiser","year":"2012","unstructured":"Kiser, J. J., Burton, J. R., Anderson, P. L. & Everson, G. T. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 55, 1620\u20131628 (2012).","journal-title":"Hepatology"},{"key":"608_CR230","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/apt.12523","volume":"38","author":"B Maasoumy","year":"2013","unstructured":"Maasoumy, B. et al. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment. Pharmacol. Ther. 38, 1365\u20131372 (2013).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"608_CR231","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jhep.2018.02.012","volume":"69","author":"G Crespo","year":"2018","unstructured":"Crespo, G. et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J. Hepatol. 69, 11\u201317 (2018).","journal-title":"J. Hepatol."},{"key":"608_CR232","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/lt.25424","volume":"25","author":"TG Cotter","year":"2019","unstructured":"Cotter, T. G. et al. Improved graft survival after liver transplantation for recipients with hepatitis C virus in the direct-acting antiviral era. Liver Transpl. 25, 598\u2013609 (2019).","journal-title":"Liver Transpl."},{"key":"608_CR233","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1136\/gutjnl-2019-320007","volume":"69","author":"SJ Hutchinson","year":"2020","unstructured":"Hutchinson, S. J. et al. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. Gut 69, 2223\u20132231 (2020).","journal-title":"Gut"},{"key":"608_CR234","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.jhep.2020.07.018","volume":"73","author":"S Rodr\u00edguez-Tajes","year":"2020","unstructured":"Rodr\u00edguez-Tajes, S. et al. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. J. Hepatol. 73, 1360\u20131367 (2020).","journal-title":"J. Hepatol."},{"key":"608_CR235","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/liv.14324","volume":"40","author":"H Razavi","year":"2020","unstructured":"Razavi, H., Sanchez Gonzalez, Y., Yuen, C. & Cornberg, M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 40, 522\u2013529 (2020).","journal-title":"Liver Int."},{"key":"608_CR236","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","volume":"74","author":"S Blach","year":"2021","unstructured":"Blach, S. et al. Impact of COVID-19 on global HCV elimination efforts. J. Hepatol. 74, 31\u201336 (2021).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"608_CR237","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/jvh.12249","volume":"21","author":"H Wedemeyer","year":"2014","unstructured":"Wedemeyer, H. et al. Strategies to manage hepatitis C virus (HCV) disease burden. J. Viral Hepat. 21 (Suppl. 1), 60\u201389 (2014).","journal-title":"J. Viral Hepat."},{"issue":"Suppl. 1","key":"608_CR238","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jvh.12248","volume":"21","author":"H Razavi","year":"2014","unstructured":"Razavi, H. et al. The present and future disease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm. J. Viral Hepat. 21 (Suppl. 1), 34\u201359 (2014).","journal-title":"J. Viral Hepat."},{"key":"608_CR239","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jhep.2019.11.019","volume":"72","author":"F Averhoff","year":"2020","unstructured":"Averhoff, F. et al. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J. Hepatol. 72, 680\u2013687 (2020).","journal-title":"J. Hepatol."},{"key":"608_CR240","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrgastro.2017.100","volume":"14","author":"M Nasrullah","year":"2017","unstructured":"Nasrullah, M., Sergeenko, D., Gamkrelidze, A. & Averhoff, F. HCV elimination \u2014 lessons learned from a small Eurasian country, Georgia. Nat. Rev. Gastroenterol. Hepatol. 14, 447\u2013448 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"608_CR241","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1056\/NEJMsr1912628","volume":"382","author":"I Waked","year":"2020","unstructured":"Waked, I. et al. Screening and treatment program to eliminate hepatitis C in Egypt. N. Engl. J. Med. 382, 1166\u20131174 (2020).","journal-title":"N. Engl. J. Med."},{"key":"608_CR242","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.27641","volume":"61","author":"N van de Ven","year":"2015","unstructured":"van de Ven, N. et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology 61, 1174\u20131182 (2015).","journal-title":"Hepatology"},{"key":"608_CR243","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/cid\/ciu012","volume":"58","author":"A Hill","year":"2014","unstructured":"Hill, A., Khoo, S., Fortunak, J., Simmons, B. & Ford, N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin. Infect. Dis. 58, 928\u2013936 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"608_CR244","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jhep.2019.07.006","volume":"71","author":"RK Dhiman","year":"2019","unstructured":"Dhiman, R. K. et al. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting. J. Hepatol. 71, 1076\u20131085 (2019).","journal-title":"J. Hepatol."},{"key":"608_CR245","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jhep.2017.12.013","volume":"68","author":"N Scott","year":"2018","unstructured":"Scott, N. et al. Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020. J. Hepatol. 68, 932\u2013939 (2018).","journal-title":"J. Hepatol."},{"key":"608_CR246","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","volume":"393","author":"A Heffernan","year":"2019","unstructured":"Heffernan, A., Cooke, G. S., Nayagam, S., Thursz, M. & Hallett, T. B. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet 393, 1319\u20131329 (2019).","journal-title":"Lancet"},{"key":"608_CR247","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt, L. et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob. Heal. 5, e1192\u2013e1207 (2017).","journal-title":"Lancet Glob. Heal."},{"key":"608_CR248","doi-asserted-by":"publisher","first-page":"625","DOI":"10.7326\/M16-0816","volume":"165","author":"GJ Dore","year":"2016","unstructured":"Dore, G. J. et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann. Intern. Med. 165, 625\u2013634 (2016).","journal-title":"Ann. Intern. Med."},{"key":"608_CR249","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/add.14128","volume":"113","author":"S Christensen","year":"2018","unstructured":"Christensen, S. et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice. Addiction 113, 868\u2013882 (2018).","journal-title":"Addiction"},{"key":"608_CR250","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","volume":"3","author":"J Grebely","year":"2018","unstructured":"Grebely, J. et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol. Hepatol. 3, 153\u2013161 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"608_CR251","first-page":"117822181983584","volume":"13","author":"S Christensen","year":"2019","unstructured":"Christensen, S. et al. Alcohol and cannabis consumption does not diminish cure rates in a real-world cohort of chronic hepatitis C virus infected patients on opioid substitution therapy-data from the german hepatitis C-registry (DHC-R). Subst. Abus. 13, 1178221819835847 (2019).","journal-title":"Subst. Abus."},{"key":"608_CR252","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/cid\/ciy899","volume":"69","author":"AH Talal","year":"2019","unstructured":"Talal, A. H. et al. Integrated, co-located, telemedicine-based treatment approaches for hepatitis C virus management in opioid use disorder patients on methadone. Clin. Infect. Dis. 69, 323\u2013331 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"608_CR253","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","volume":"368","author":"HL Janssen","year":"2013","unstructured":"Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685\u20131694 (2013).","journal-title":"N. Engl. J. Med."},{"key":"608_CR254","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/cid\/ciz949","volume":"71","author":"P Ingiliz","year":"2020","unstructured":"Ingiliz, P. et al. Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in germany: current incidence rates, compared with rates during the interferon era. Clin. Infect. Dis. 71, 1248\u20131254 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"608_CR255","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","volume":"66","author":"P Ingiliz","year":"2017","unstructured":"Ingiliz, P. et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J. Hepatol. 66, 282\u2013287 (2017).","journal-title":"J. Hepatol."},{"key":"608_CR256","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/cid\/cix1004","volume":"66","author":"A Boerekamps","year":"2018","unstructured":"Boerekamps, A. et al. High treatment uptake in human immunodeficiency virus\/hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands. Clin. Infect. Dis. 66, 1352\u20131359 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"608_CR257","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","volume":"13","author":"K Deterding","year":"2013","unstructured":"Deterding, K. et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect. Dis. 13, 497\u2013506 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"608_CR258","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/hep.29611","volume":"67","author":"ED Bethea","year":"2018","unstructured":"Bethea, E. D., Chen, Q., Hur, C., Chung, R. T. & Chhatwal, J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology 67, 837\u2013846 (2018).","journal-title":"Hepatology"},{"key":"608_CR259","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","volume":"17","author":"K Deterding","year":"2017","unstructured":"Deterding, K. et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect. Dis. 17, 215\u2013222 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"608_CR260","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S2468-1253(18)30414-X","volume":"4","author":"A Boerekamps","year":"2019","unstructured":"Boerekamps, A. et al. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol. Hepatol. 4, 269\u2013277 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"608_CR261","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2018.1917","volume":"319","author":"J Riddell","year":"2018","unstructured":"Riddell, J., Amico, K. R. & Mayer, K. H. HIV preexposure prophylaxis: a review. JAMA 319, 1261\u20131268 (2018).","journal-title":"JAMA"},{"key":"608_CR262","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1056\/NEJMoa2023345","volume":"384","author":"K Page","year":"2021","unstructured":"Page, K. et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N. Engl. J. Med. 384, 541\u2013549 (2021).","journal-title":"N. Engl. J. Med."},{"key":"608_CR263","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1021\/jm100863x","volume":"53","author":"MJ Sofia","year":"2010","unstructured":"Sofia, M. J. et al. Discovery of a \u03b2-d-2\u2019-deoxy-2\u2019-\u03b1-fluoro-2\u2019-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53, 7202\u20137218 (2010).","journal-title":"J. Med. Chem."},{"key":"608_CR264","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","volume":"148","author":"MP Curry","year":"2014","unstructured":"Curry, M. P. et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148, 100\u2013110 (2014).","journal-title":"Gastroenterology"},{"key":"608_CR265","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/clinchem\/43.8.1487","volume":"43","author":"LH Tobler","year":"1997","unstructured":"Tobler, L. H. & Busch, M. P. History of posttransfusion hepatitis. Clin. Chem. 43, 1487\u20131493 (1997).","journal-title":"Clin. Chem."},{"key":"608_CR266","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","volume":"343","author":"EJ Heathcote","year":"2000","unstructured":"Heathcote, E. J. et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343, 1673\u20131680 (2000).","journal-title":"N. Engl. J. Med."},{"key":"608_CR267","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.gastro.2013.11.047","volume":"146","author":"M Buti","year":"2014","unstructured":"Buti, M. et al. Telaprevir twice daily is noninferior to telaprevir every 8\u2009h for patients with chronic hepatitis C. Gastroenterology 146, 744\u2013753.e3 (2014).","journal-title":"Gastroenterology"},{"key":"608_CR268","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/pds.3592","volume":"23","author":"S Dechanont","year":"2014","unstructured":"Dechanont, S., Maphanta, S., Butthum, B. & Kongkaew, C. Hospital admissions\/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol. Drug Saf. 23, 489\u2013497 (2014).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"608_CR269","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/lt.23542","volume":"18","author":"CR Werner","year":"2012","unstructured":"Werner, C. R. et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 18, 1464\u20131470 (2012).","journal-title":"Liver Transpl."},{"key":"608_CR270","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1665-2681(19)30853-1","volume":"13","author":"CT Kanter","year":"2014","unstructured":"Kanter, C. T., Luin, M., Solas, C., Burger, D. M. & Vrolijk, J. M. Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin. Ann. Hepatol. 13, 452\u2013455 (2014).","journal-title":"Ann. Hepatol."},{"key":"608_CR271","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jhep.2014.01.002","volume":"60","author":"J Vermehren","year":"2014","unstructured":"Vermehren, J. et al. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J. Hepatol. 60, 913\u2013919 (2014).","journal-title":"J. Hepatol."},{"key":"608_CR272","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/apt.12544","volume":"39","author":"B Maasoumy","year":"2014","unstructured":"Maasoumy, B. et al. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment. Pharmacol. Ther. 39, 85\u201392 (2014).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"608_CR273","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110857","volume":"9","author":"B Maasoumy","year":"2014","unstructured":"Maasoumy, B. et al. Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PLoS ONE 9, e110857 (2014).","journal-title":"PLoS ONE"},{"key":"608_CR274","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jhep.2016.07.023","volume":"65","author":"B Maasoumy","year":"2016","unstructured":"Maasoumy, B. & Vermehren, J. Diagnostics in hepatitis C: the end of response-guided therapy? J. Hepatol. 65, S67\u2013S81 (2016).","journal-title":"J. Hepatol."},{"key":"608_CR275","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/cid\/ciw061","volume":"62","author":"J Vermehren","year":"2016","unstructured":"Vermehren, J. et al. Applicability of Hepatitis C virus RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C virus genotype 1 infection. Clin. Infect. Dis. 62, 1228\u20131234 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"608_CR276","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","volume":"151","author":"NA Terrault","year":"2016","unstructured":"Terrault, N. A. et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology 151, 1131\u20131140.e5 (2016).","journal-title":"Gastroenterology"},{"key":"608_CR277","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jhep.2017.11.009","volume":"68","author":"P Buggisch","year":"2018","unstructured":"Buggisch, P. et al. Real-world effectiveness of 8-week treatment with ledipasvir\/sofosbuvir in chronic hepatitis C. J. Hepatol. 68, 663\u2013671 (2018).","journal-title":"J. Hepatol."},{"key":"608_CR278","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/cid\/ciw567","volume":"63","author":"P Ingiliz","year":"2016","unstructured":"Ingiliz, P. et al. Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C Virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the German hepatitis C cohort (GECCO-01). Clin. Infect. Dis. 63, 1320\u20131324 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"608_CR279","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/liv.13932","volume":"38","author":"B Maasoumy","year":"2018","unstructured":"Maasoumy, B. et al. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir\/sofosbuvir in GT1 patients. Liver Int. 38, 1906\u20131910 (2018).","journal-title":"Liver Int."},{"key":"608_CR280","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMc1709315","volume":"377","author":"F Halleck","year":"2017","unstructured":"Halleck, F. et al. Transplanting HCV-infected kidneys into uninfected recipients. N. Engl. J. Med. 377, 1103\u20131104 (2017).","journal-title":"N. Engl. J. Med."},{"key":"608_CR281","doi-asserted-by":"publisher","first-page":"109","DOI":"10.7326\/M16-1205","volume":"166","author":"M Colombo","year":"2017","unstructured":"Colombo, M. et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann. Intern. Med. 166, 109\u2013117 (2017).","journal-title":"Ann. Intern. Med."},{"key":"608_CR282","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.healun.2018.01.1293","volume":"37","author":"KH Schlendorf","year":"2018","unstructured":"Schlendorf, K. H. et al. Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies. J. Hear. Lung Transpl. 37, 763\u2013769 (2018).","journal-title":"J. Hear. Lung Transpl."},{"key":"608_CR283","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/jvh.13130","volume":"26","author":"G Nangia","year":"2019","unstructured":"Nangia, G., Borges, K. & Reddy, K. R. Use of HCV-infected organs in solid organ transplantation: an ethical challenge but plausible option. J. Viral Hepat. 26, 1362\u20131371 (2019).","journal-title":"J. Viral Hepat."},{"key":"608_CR284","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1111\/ajt.14396","volume":"17","author":"JA Fishman","year":"2017","unstructured":"Fishman, J. A. & Forns, X. HCV-positive donor organs in solid organ transplantation: \u2018Mind the Gap!\u2019. Am. J. Transpl. 17, 2755\u20132756 (2017).","journal-title":"Am. J. Transpl."},{"key":"608_CR285","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S2468-1253(19)30250-X","volume":"4","author":"D Samuel","year":"2019","unstructured":"Samuel, D. HCV-positive organ transplants in HCV-negative recipients. Lancet Gastroenterol. Hepatol. 4, 745\u2013747 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"608_CR286","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/ajt.15054","volume":"18","author":"G Gupta","year":"2018","unstructured":"Gupta, G., Zhang, Y., Carroll, N. V. & Sterling, R. K. Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. Am. J. Transpl. 18, 2496\u20132505 (2018).","journal-title":"Am. J. Transpl."},{"key":"608_CR287","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/ajt.14929","volume":"18","author":"M Kadatz","year":"2018","unstructured":"Kadatz, M., Klarenbach, S., Gill, J. & Gill, J. S. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients. Am. J. Transpl. 18, 2457\u20132464 (2018).","journal-title":"Am. J. Transpl."},{"key":"608_CR288","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.14309\/ajg.0000000000000583","volume":"115","author":"PJ Thuluvath","year":"2020","unstructured":"Thuluvath, P. J. et al. Use of HCV-positive livers in HCV-negative recipients. Am. J. Gastroenterol. 115, 1045\u20131054 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"608_CR289","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/ajt.15162","volume":"19","author":"AJ Kwong","year":"2019","unstructured":"Kwong, A. J. et al. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am. J. Transpl. 19, 1380\u20131387 (2019).","journal-title":"Am. J. Transpl."},{"key":"608_CR290","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/hep.30540","volume":"69","author":"TG Cotter","year":"2019","unstructured":"Cotter, T. G. et al. Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic donors. Hepatology 69, 2381\u20132395 (2019).","journal-title":"Hepatology"},{"key":"608_CR291","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1111\/ajt.15496","volume":"19","author":"RM La Hoz","year":"2019","unstructured":"La Hoz, R. M., Sand\u0131k\u00e7\u0131, B., Ariyamuthu, V. K. & Tanriover, B. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals. Am. J. Transpl. 19, 3058\u20133070 (2019).","journal-title":"Am. J. Transpl."},{"issue":"Suppl.","key":"608_CR292","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/ajt.15679","volume":"20","author":"JH Wang","year":"2020","unstructured":"Wang, J. H. et al. OPTN\/SRTR 2018 Annual Data Report: Hepatitis C. Am. J. Transpl. 20 (Suppl.), 542\u2013568 (2020).","journal-title":"Am. J. Transpl."},{"key":"608_CR293","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/hep.29723","volume":"67","author":"J Chhatwal","year":"2018","unstructured":"Chhatwal, J. et al. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: a modeling study. Hepatology 67, 2085\u20132095 (2018).","journal-title":"Hepatology"},{"key":"608_CR294","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S2468-1253(19)30240-7","volume":"4","author":"ED Bethea","year":"2019","unstructured":"Bethea, E. D. et al. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. Lancet Gastroenterol. Hepatol. 4, 771\u2013780 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"608_CR295","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S2213-2600(19)30268-1","volume":"8","author":"M Cypel","year":"2020","unstructured":"Cypel, M. et al. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. Lancet Respir. Med. 8, 192\u2013201 (2020).","journal-title":"Lancet Respir. Med."},{"key":"608_CR296","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","volume":"69","author":"LS Belli","year":"2018","unstructured":"Belli, L. S. et al. Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J. Hepatol. 69, 810\u2013817 (2018).","journal-title":"J. Hepatol."}],"container-title":["Nature Reviews Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00608-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00608-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00608-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:20:22Z","timestamp":1733941222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00608-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":296,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1038\/s41575-022-00608-8","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"assertion":[{"value":"16 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P.M. received speaker and\/or consulting fees and\/or grant or research support from AbbVie, BMS, Gilead, Merck\/MSD and Janssen. B.M. received speaker and\/or consulting fees from Abbott Molecular, Astellas, Intercept, Falk, AbbVie, Bristol-Myers Squibb, Fujirebio, Janssen-Cilag, Merck\/MSD and Roche. He also received research support from Abbott Molecular and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}